AYTU BIOPHARMA, INC (AYTU)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A
Pipeline Grade

Financial Position (from SEC Filings)

$19.8M
Cash & Equivalents
$1.1M
Quarterly Burn Rate
53 mo
Est. Cash Runway
$24M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (1 Assets)

DrugPhaseIndications
METHYLPHENIDATE HYDROCHLORIDE
METADATE CD 		NDA Acute Respiratory Distress Syndrome, Attention Deficit Hyperactivity Disorder, Compare the sORP Rate in Sperm Samples, Obtained by the Mioxsys System, Before and After 2.5 Months Antioxidant Men Supplements Treatment (Fertybiotic Man), Coronavirus, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Pneumonia, COVID-19 Respiratory Infection, Male Infertility, Prostate Cancer, Vascular Ehlers-Danlos Syndrome

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for AYTU.

SEC EDGAR Filings

All SEC filings for AYTU BIOPHARMA, INC on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.